News & Media
Janssen creates new division to launch TMC435 and help conquer hepatitis C in EMEA
17/04/2012
Today sees the launch of Janssen Therapeutics EMEA, a division of Janssen Pharmaceutica NV, dedicated to bringing the investigational protease inhibitor TMC435 to hepatitis C patients in the EMEA region. Read more
Janssen's medicine for Hepatitis C wins Galenus Prize
17/04/2012
Janssen as received its fifth Galenus Prize in recognition of the medicinal value and enormous success of INCIVO® (telaprevir), a medicinal product for the treatment of Hepatitis C. Read more
Janssen's medicine for Hepatitis C wins Galenus Prize
17/04/2012
Janssen as received its fifth Galenus Prize in recognition of the medicinal value and enormous success of INCIVO® (telaprevir), a medicinal product for the treatment of Hepatitis C. Read more
Dr. Ajit Shetty to retire
29/02/2012
After a brilliant and highly successful career spanning 35 years, the Chairman of the Board of Janssen Pharmaceutica is to retire. On Thursday, 1st March, Ajit Shetty will hand over the torch to Tom Heyman, who will serve simultaneously as CEO and Chairman of the Board of Janssen Pharmaceutica. Read more
Johnson & Johnson joins partners in the battle against Neglected Tropical Diseases
30/01/2012
Johnson & Johnson joins public and private partners in the largest coordinated action to date to eliminate or control neglected tropical diseases. Read more
